Healthcare Industry Business Confidence Report 2019

2019-03-28
Price :
Published : Mar-2019
No. of Pages : 54

Healthcare Industry Business Confidence Report 2019

Summary

GlobalData’s “Healthcare Industry Business Confidence Report 2019”, examines executives’ opinion about the business environment during 2019. It also highlights current economic conditions, supplier price variations, sales performance, industry and company growth prospects, spending models, and key priorities. Additionally, the report provides information categorized by region, and company size and type.

The majority of respondents see the current global economic situation as stable or favorable. North American and Asia-Pacific economies were viewed as most favorable but respondents from these regions had less favorable views of the global economy. Factors such as reduced mortality, aging population, advances in biomedical engineering and instruments, and increased investment in technology-based smart healthcare system will continue to increase the demand and expenditure towards healthcare in these regions. Globally, 68% of healthcare industry respondents have positive expectations for their company’s growth over the next 12 months, while 63% feel the same about the industry’s growth. Furthermore, Supplier prices of medical equipment are expected to see the highest surge at 4.8% over the next 12 months. Additionally, Brexit, political changes, and emerging new competition are the most pressing concerns for the healthcare industry.

What else does this report offer?

– The current state of the economy with regards to its impact on healthcare industry: examines predominating economic conditions globally and across specific regions
– Company and industry growth outlook: provides executives’ opinions on the growth prospects of their company and the industry over the next 12 months
– Change in level of customer confidence: analyzes respondents’ sentiments surrounding the shift in customer confidence during 2019 within healthcare industry
– Supplier prices outlook: determines the expected variation in supplier prices across different categories and their impact on business confidence
– Change in staff headcount and sales performance: anticipates and tracks the shift in staff headcount and sales during 2019 among industry executives globally as well as regionally
– Investment Projection & activities: highlights different areas in which industry executives intend to spend and invest over the next six months
– Business concerns: provides information about potential business concerns indicated by survey respondents for H1 2018
– Key priorities: identifies the top priorities of industry executives operating in various regions.

Scope

– Almost three-quarters of respondents view the current global economic state as stable or favorable with regards to its impact on the healthcare industry. The more positive outlook was seen among respondents from organizations with annual revenue more than $1B
– Across all the geographies, the average sales performance (5.3%) and staff headcount (2.9%) is expected to increase within the healthcare sector over the next 12 months
– Respondents from larger companies (annual revenue more than $1B) expect more growth opportunities for the industry (78%) than for their own companies (67%) over the next 12 months; the reverse is true for smaller companies
– Overall, 48% of respondents are positive or very positive about the change in customer confidence among export customers over the next 12 months
– On average, healthcare industry executives expect supplier prices for raw materials to increase by 4.2% over the next 12 months.

Reasons to buy

– Assists companies to make effective business strategy decisions by knowing the prevailing market conditions and sentiment within the healthcare industry
– Supports organizations in business expansion decisions by providing information concerning the projected variation in sales performance and supplier prices
– Helps to improve operational efficiency and to protect and grow market share by comprehending the essential priorities and major concerns within the healthcare industry
– Serves to adjust investment allocation by outlining key focus areas highlighted by survey respondents during 2019.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based ......
$2500

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Urticaria Or Hives clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Urticaria Or Hives. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Cryptosporidiosis Global Clinical Trials Review, H1, 2019

Cryptosporidiosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H1, 2019" provides an overview of Cryptosporidiosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptosporidiosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Colitis Global Clinical Trials Review, H1, 2019

Colitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colitis Global Clinical Trials Review, H1, 2019" provides an overview of Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Degenerative Scoliosis Global Clinical Trials Review, H1, 2019" provides an overview of Degenerative Scoliosis clinical trials scenario. This report provides top line data relating to the clinical trials on Degenerative Scoliosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Conjunctivitis Global Clinical Trials Review, H1, 2019

Conjunctivitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Conjunctivitis Global Clinical Trials Review, H1, 2019" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy